DV
Dividend Vision

BOLT — Bolt Biotherapeutics

Bolt Biotherapeutics (BOLT)

Total return is -99.5% over the past 5.5 years, 215.2 points behind SPY at 115.7%. Its deepest 1-year drawdown was 54.7%.

BOLT is an equity stock fund that focuses on biotherapeutics holdings. The fund does not currently provide dividend distributions, making it unsuitable for income-focused investors seeking regular yield. This fund appeals primarily to growth-oriented investors interested in exposure to the biotherapeutics sector rather than those prioritizing dividend income.

BOLT key facts

Asset type
Stock
Asset class
Equity
Inception date
02/05/2021
Last close
$3.35
Market cap
$8,493,326
Average volume
15961.0
Beta
1.165
Payout ratio
0.0
Forward P/E
0.0
EPS
$-16.40